TargetMol

Lifibrol

Product Code:
 
TAR-T27832
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27832-1mg1mg£188.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27832-5mg5mg£352.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27832-10mg10mg£496.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27832-25mg25mg£760.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27832-50mg50mg£1,018.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27832-100mg100mg£1,348.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27832-500mg500mg£2,633.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Lifibrol is a cholesterol synthesis inhibitor. Lifibrol enhances the low density lipoprotein apolipoprotein B-100 turnover in patients with hypercholesterolemia and mixed hyperlipidemia.
CAS:
96609-16-4
Formula:
C21H26O4
Molecular Weight:
342.435
Pathway:
Metabolism
Purity:
0.98
SMILES:
CC(C)(C)c1ccc(CCC(O)COc2ccc(cc2)C(O)=O)cc1
Target:
Lipid

References

1. Berthold HK, Sudhop T, von Bergmann K, Gouni-Berthold I. Lifibrol as a model compound for a novel lipid-lowering mechanism of action. J Cardiovasc Pharmacol Ther. 2010 Dec;15(4):364-72. doi: 10.1177/1074248410371100. Epub 2010 Aug 6. PubMed PMID: 20693157. 2. Bays H, Stein EA. Pharmacotherapy for dyslipidaemia--current therapies and future agents. Expert Opin Pharmacother. 2003 Nov;4(11):1901-38. Review. PubMed PMID: 14596646. 3. Scharnagl H, Schliack M, L?ser R, Nauck M, Gierens H, Jeck N, Wieland H, Gross W, M?rz W. The effects of lifibrol (K12.148) on the cholesterol metabolism of cultured cells: evidence for sterol independent stimulation of the LDL receptor pathway. Atherosclerosis. 2000 Nov;153(1):69-80. PubMed PMID: 11058701. 4. Winkler K, Schaefer JR, Klima B, Nuber C, Friedrich I, K?ster W, Gierens H, Scharnagl H, Soufi M, Wieland H, M?rz W. HDL steady state levels are not affected, but HDL apoA-I turnover is enhanced by Lifibrol in patients with hypercholesterolemia and mixed hyperlipidemia. Atherosclerosis. 2000 May;150(1):113-20. PubMed PMID: 10781641.